Should I buy or sell Knight Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GUD shares. View GUD analyst ratings or view top-rated stocks .

What is Knight Therapeutics' stock price target for 2024?

2 brokerages have issued 1 year price targets for Knight Therapeutics' shares. Their GUD share price targets range from C$5.25 to C$7.50. On average, they expect the company's stock price to reach C$6.58 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View analysts price targets for GUD or view top-rated stocks among Wall Street analysts .

How have GUD shares performed in 2024?

Knight Therapeutics' stock was trading at C$5.19 at the start of the year. Since then, GUD stock has increased by 11.2% and is now trading at C$5.77. View the best growth stocks for 2024 here .

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GUD earnings forecast .

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business earned $74.20 million during the quarter, compared to the consensus estimate of $78.37 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 2.14% and a negative net margin of 5.13%.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU) , Bombardier, Inc. Class B (BBD.B) , Brookfield Infrastructure Partners (BIP.UN) , Enbridge (ENB) , Spin Master (TOY) , Alimentation Couche-Tard (ATD.B) , Chemtrade Logistics Income Fund (CHE.UN) , Canadian National Railway (CNR) , Dollarama (DOL) and Extendicare (EXE) .

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:GUD

Knight Therapeutics (GUD) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free GUD Stock Alerts

C$5.77

+0.01 (+0.17%)

(As of 04/16/2024 ET)

Compare

Today's Range: C$5.70
▼
C$5.82
50-Day Range: C$5.23
▼
C$5.87
52-Week Range: C$4.35
▼
C$5.95

Volume: 56,014 shs
Average Volume: 76,329 shs
Market Capitalization: C$583.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$6.58

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

Get Knight Therapeutics alerts:

Knight Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 14.1% Upside
C$6.58 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
C$1.88 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

2.5

Analyst's Opinion

Consensus Rating
Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Knight Therapeutics has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for GUD.

0.0

Dividend Strength

Dividend Yield
Knight Therapeutics does not currently pay a dividend.
Dividend Growth
Knight Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GUD.

2.0

News and Social Media Coverage

News Sentiment
Knight Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Knight Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for GUD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Knight Therapeutics insiders have bought 149.96% more of their company's stock than they have sold. Specifically, they have bought C$1,875,300.00 in company stock and sold C$750,255.00 in company stock.
Percentage Held by Insiders
46.45% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.67% of the stock of Knight Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Knight Therapeutics is -36.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Knight Therapeutics is -36.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Knight Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Knight Therapeutics Stock (TSE:GUD)

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

GUD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GUD Stock News Headlines

April 16, 2024 | insidertrades.com

Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 10,900 Shares

April 9, 2024 | insidertrades.com

Knight Therapeutics Inc. (TSE:GUD) Insider Buys C$32,550.00 in Stock

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 26, 2024 | insidertrades.com

Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Acquires 351,000 Shares

April 16, 2024 | msn.com

TSX Healthcare in April 2024: The Best Stocks to Buy Right Now

April 9, 2024 | finance.yahoo.com

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

March 23, 2024 | investing.com

Earnings call: Knight Therapeutics announced record revenues of $343 million

March 22, 2024 | finance.yahoo.com

Knight Therapeutics Full Year 2023 Earnings: Misses Expectations

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 20, 2024 | ca.finance.yahoo.com

Knight Therapeutics Inc (04K.SG)

March 14, 2024 | ca.finance.yahoo.com

Stocks in play: Knight Therapeutics Inc.

March 7, 2024 | finance.yahoo.com

Favourable Signals For Knight Therapeutics: Numerous Insiders Acquired Stock

February 29, 2024 | ca.finance.yahoo.com

Stocks in play: Knight Therapeutics Inc.,

February 29, 2024 | msn.com

Knight Therapeutics launches Minjuvi in Brazil

February 21, 2024 | finance.yahoo.com

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

January 4, 2024 | finance.yahoo.com

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

December 19, 2023 | finance.yahoo.com

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

October 2, 2023 | finance.yahoo.com

Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies

September 14, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc flat on Thursday (GUD)

August 12, 2023 | markets.businessinsider.com

Knight Therapeutics (KHTRF) Receives a Buy from RBC Capital

August 10, 2023 | theglobeandmail.com

Trading For This Specialty Pharma Company is up Following Second Quarter Results

August 10, 2023 | finance.yahoo.com

Knight Therapeutics Reports Second Quarter 2023 Results

August 3, 2023 | finance.yahoo.com

Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call

June 7, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc up on Tuesday (GUD)

June 2, 2023 | finance.yahoo.com

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

May 31, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Wednesday (GUD)

May 26, 2023 | finance.yahoo.com

Samira Sakhia Bought 12% More Shares In Knight Therapeutics

See More Headlines

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: TSE:GUD
CUSIP: N/A
CIK: N/A
Web: www.gud-knight.com
Phone: 514-484-4483
Fax: N/A
Employees: 725
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$6.58
High Stock Price Target: C$7.50
Low Stock Price Target: C$5.25
Potential Upside/Downside: +14.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 285.42
P/E Growth: -1013.5
Net Income: C$-16,840,000.00
Net Margins: -5.13%
Pretax Margin: N/A
Return on Equity: -2.14%
Return on Assets: 0.40%

Debt

Debt-to-Equity Ratio: 9.25
Current Ratio: 3.20
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: C$328.20 million
Price / Sales: 1.78
Cash Flow: C$1.50 per share
Price / Cash Flow: 3.85
Book Value: C$7.38 per share
Price / Book: 0.78

Miscellaneous

Outstanding Shares: 101,170,000
Free Float: N/A
Market Cap: C$583.75 million
Optionable: Not Optionable
Beta: 0.49

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Jonathan Ross Goodman B.A. (Age 55)
L.L.B., M.B.A., Executive Chairman
Comp: $250.94k
Ms. Samira Sakhia BCom (Age 56)
CA, CPA, MBA, President, CEO & Director
Comp: $674.28k
Mr. Arvind Utchanah
Chief Financial Officer
Ms. Amal Khouri B.Sc.
M.B.A., Chief Business Officer
Mr. Jeff Martens
Global Vice President of Commercial
Mr. Stephani Saverio
Vice President of Business Development
Mr. Leopoldo Bosano
Vice-President of Manufacturing & Operations
Ms. Monica Percario
Global Vice President of Scientific Affairs
Mr. Henrique Dias
Global Director of Marketing
Ms. Susan Caroline Emblem
Global Vice President of Human Resources

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GUD Stock Analysis - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GUD shares.
View GUD analyst ratings or view top-rated stocks.
What is Knight Therapeutics' stock price target for 2024?: 2 brokerages have issued 1 year price targets for Knight Therapeutics' shares. Their GUD share price targets range from C$5.25 to C$7.50. On average, they expect the company's stock price to reach C$6.58 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price.
View analysts price targets for GUD or view top-rated stocks among Wall Street analysts.
How have GUD shares performed in 2024?: Knight Therapeutics' stock was trading at C$5.19 at the start of the year. Since then, GUD stock has increased by 11.2% and is now trading at C$5.77.
View the best growth stocks for 2024 here.
When is Knight Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GUD earnings forecast.

How were Knight Therapeutics' earnings last quarter?: Knight Therapeutics Inc. (TSE:GUD) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business earned $74.20 million during the quarter, compared to the consensus estimate of $78.37 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 2.14% and a negative net margin of 5.13%.
What other stocks do shareholders of Knight Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE).
How do I buy shares of Knight Therapeutics?: Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GUD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Knight Therapeutics (GUD) Stock Price, News & Analysis

Knight Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Knight Therapeutics Stock (TSE:GUD)

GUD Stock Price History

GUD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

GUD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™